Locations:
Search IconSearch
December 30, 2020/Cancer

Cleveland Clinic Surgeon Completes First Clinical Use of Newly Approved Ablation Device for Large Liver Tumors

The technology could reduce complications by offering patients an alternative to open liver surgeries

2015058_11-20-20_025_MK-Hero_650x450

Cleveland Clinic is the first hospital in the world to use a recently FDA-approved ablation technology that can destroy large liver tumors. The new device from Medtronic is called the Emprint™ HP Ablation System with Thermosphere™ Technology. The minimally invasive procedure uses a single needle connected to a powerful 150-watt microwave generator that can burn a malignant liver tumor as large as 2.4 inches (6 cm).

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

Eren Berber, MD, Director of Cleveland Clinic’s Surgical Liver Tumor Ablation Program, led a team that successfully used the device in October to treat a patient who had a 2.4-inch liver tumor. Following the minimally invasive procedure, the patient is doing well and postoperative imaging shows no trace of the tumor. Since the first case in October at Cleveland Clinic, Dr. Berber’s team has treated four more patients with large liver tumors using the technology.

“We’ve been using the previous versions of this technology,” says Dr. Berber. “But the challenge was that with a single needle, we were only able to create 4-centimeter burns. This technology is able to utilize 150 watts of power compared to the 100 watts that we used before. We’re also now able to create 6- or 7-centimeter burns with a single stick. This allowed us to treat larger tumors more confidently.”

Cleveland Clinic has been using ablation technologies to treat smaller tumors up to about 1.5 inches (4 cm) in diameter and not amenable to liver resection. Dr. Berber and his team have treated close to 1,000 patients with ablation and more than 200 patients with microwave ablation. It was because of this extensive experience with the technique and device that Dr. Berber was selected as the first clinical user. “This microwave ablation technology is very powerful, and if you don’t use it well, you can cause damage to the liver, you can cause bleeding or you can disrupt the tumor,” says Dr. Berber. “As the technology becomes more advanced and more powerful, gaining ablation expertise through experience becomes even more important.”

Advertisement

Understanding the procedure

To perform the procedure, a laparoscopic camera and an ultrasound probe are inserted in the abdomen through two small incisions. Then, a microwave needle is inserted through the skin into the liver tumor. When ready, the generator delivers heat to burn and destroy the lesion.

“Over the last six years, ablation technology evolved to incorporate microwave technology, which gives us a more homogeneous heating of the tissues by achieving higher temperatures,” explains Dr. Berber. “There is more balanced heating, and we can now reach higher tissue temperatures. Because of that, the success of ablation has greatly improved; the failure rate went down from 20% to 40% to about 10% or less.”

Identifying candidates

Dr. Berber notes that the best candidates for this procedure for treatment of large liver tumors are those with comorbidities which rendered them poor candidates for a major operation that would involve liver resection (cutting). This includes patients with multiple systemic diseases, heart problems, lung problems, or elderly patients who have decreased functional status who cannot tolerate a major operation. This procedure would be a good alternative for patients who would require surgery to remove a large portion of their liver. Open liver surgical procedures are associated with longer operative times and hospital stays, as well as higher incidence of complications.

“The goal is to offer the best treatment option for patients depending on their unique health condition,” says Dr. Berber In the hands of an experienced surgical team, the laparoscopic ablation technique benefits the patient, who experiences better postoperative recovery, less pain, a quicker return to normal life, and a lower risk of an incisional hernia compared with traditional open surgery.”

Advertisement

Dr. Berber has a consulting agreement with Medtronic and has received honoraria for consulting activities. He notes that his consulting agreements do not affect his choice of the best treatment option for his patients.

Advertisement

Related Articles

Oncology nurse
January 9, 2026/Cancer
Improving Patient Experience in Inpatient Hematology: A Nursing Perspective

Structured interventions enhance sleep, safety and caregiver resiliency in high-acuity units

PET scan
January 7, 2026/Cancer/Blood Cancers
Case Study: 21-Year-Old Patient with Refractory T-Cell Lymphoma

Addressing rare disease and challenging treatment course in an active young patient

Dr. Angelini
December 24, 2025/Cancer/News & Insight
Study Analyzes Direct Oral Anticoagulants Use in Patients with Brain Metastases

Large retrospective study suggests DOACs are safe, effective alternative to low-molecular-weight heparin in complex patient population

Dr. Singh
December 19, 2025/Cancer/Blood Cancers
IDH1 Inhibitor Found Safe and Effective in Rare Precursor to Blood Malignancies

Study shows high rate of hematologic responses, low rate of disease progression

Shahzad Raza, MD
December 18, 2025/Cancer/Blood Cancers
Talquetamab Provides Lifesaving Bridge to CAR T-Cell Therapy

Bispecific antibody bridging therapy deepens durability of BCMA CAR T-cell therapy without overlapping toxicities in patients with relapsed/refractory multiple myeloma

Dr. Raza
December 16, 2025/Cancer/Blood Cancers
Dual Bispecifics May Redefine Management of Extramedullary Myeloma

Phase 2 study brings pivotal advances in treatment efficacy and safety for the most challenging-to-treat population

CAR T-cell therapy
December 15, 2025/Cancer/Blood Cancers
Case Study: Patient Remains Disease Free Five Years After Allogenic CAR T-Cell Therapy

Patient with quadruple refractory multiple myeloma achieves complete response with cell therapy

J. Joseph Melenhorst, PhD
December 12, 2025/Cancer/Blood Cancers
Researchers Identify Predictors of Response to CAR T-Cell Therapy in B-Cell Non-Hodgkin’s Lymphoma

Distinct baseline immune profiles can predict response and resistance to different types of CAR-T cells.

Ad